|
Characteristics of all study participants |
||
| Characteristic |
N |
% |
|
|
||
| Total |
52 |
|
| Age (years; median, range) |
43 (27–65) |
|
| BRCA mutation |
||
| A1 |
25 |
48 |
| A2 |
27 |
52 |
| Menopause status |
||
| Premenopausal |
25 |
48 |
| Postmenopausal |
27 |
52 |
| BSO <50 years |
19 |
37 |
| Current use (study entry) |
||
| OCP |
3 |
6 |
| HRT |
3 |
6 |
| Tamoxifen |
4 |
8 |
| Previous diagnosis of breast cancer |
21 |
40 |
| Parous |
44 |
85 |
| Breast fed |
38 |
73 |
|
BSO, bilateral salpingo-oophorectomy; HRT, hormone replacement therapy; OCP, oral contraceptive pill. | ||
Mitchell et al. Breast Cancer Research 2005 7:R1122 doi:10.1186/bcr1348 |
||